<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104710</url>
  </required_header>
  <id_info>
    <org_study_id>IRB20-1478</org_study_id>
    <secondary_id>1R01NS116262-01A1</secondary_id>
    <nct_id>NCT05104710</nct_id>
  </id_info>
  <brief_title>Intermuscular Coherence as a Biomarker for ALS</brief_title>
  <acronym>ALS-IMC</acronym>
  <official_title>Intermuscular Coherence: A Biomarker for Early Diagnosis and Follow-up of ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <brief_summary>
    <textblock>
      The specific aims of this study are to:&#xD;
&#xD;
        1. Determine if a painless and quick measurement of muscle activity using surface&#xD;
           electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of&#xD;
           intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji&#xD;
           criteria), can differentiate ALS from mimic diseases more accurately and earlier than&#xD;
           currently possible.&#xD;
&#xD;
        2. Characterize IMC-βγ in neurotypical subjects by age, sex, race, and ethnicity.&#xD;
&#xD;
        3. Follow a cohort of ALS patients longitudinally to determine if IMC-βγ changes with ALS&#xD;
           disease progression and whether such changes correlate with functional and clinical&#xD;
           scores, or survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by neuronal&#xD;
      death in the motor system, both in the brain and spinal cord. It results in progressive&#xD;
      weakness throughout the body, and typically leads to respiratory failure 3-5 years after&#xD;
      symptom onset. Therapy initiation and drug development are hindered, in part, by the lack of&#xD;
      objective disease markers.&#xD;
&#xD;
      This is a multi-center trial to validate a potential biomarker for ALS, known as&#xD;
      intermuscular coherence (IMC-βγ). IMC measures the correlation in the activity of two muscles&#xD;
      during a simple motor task. In a preliminary study we found that patients with ALS have lower&#xD;
      IMC than do control subjects. Because measuring IMC is quick, non-invasive, painless, and&#xD;
      only requires equipment readily available in standard clinical neurophysiology labs, if&#xD;
      validated it would be an important biomarker for ALS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the sensitivity for diagnosing ALS when a measure of intermuscular coherence is added to the Awaji criteria.</measure>
    <time_frame>5 years</time_frame>
    <description>Aim 1 asks if incorporation of IMC-βγ into the Awaji criteria improves the criteria's sensitivity for diagnosing ALS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to diagnosis of ALS</measure>
    <time_frame>5 years</time_frame>
    <description>Aim 1 asks if incorporation of IMC-βγ into the Awaji criteria reduces the time to diagnosis of ALS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ALS disease progression</measure>
    <time_frame>5 years</time_frame>
    <description>Aim 3 asks whether changes in the magnitude of IMC-βγ measured over many months varies with ALS disease progression in patients.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>AIM 1</arm_group_label>
    <description>Hypothesis: IMC-βγ can help to differentiate between ALS and mimic diseases at initial presentation.&#xD;
Patients who present to a neuromuscular clinic with symptoms that might be from ALS but for whom a diagnosis is not yet known, will be studied. Measurements of intermuscular coherence will be made using surface electrodes. A standard neurological examination and questionnaire about ALS symptoms will be completed. No interventions will be made. A patient's final diagnosis will be determined using standard-of-care testing. Six months after initial IMC measurement, a determination will be made whether the IMC predicted the diagnosis of ALS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIM 2</arm_group_label>
    <description>Hypothesis: Characterization of demographic-specific distributions will improve the specificity of IMC-βγ for ALS.&#xD;
To optimize cutoff values for abnormal IMC, IMC-βγ will be measured in neurotypical controls across a range of age, race, ethnicity, and sexes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIM 3</arm_group_label>
    <description>Hypothesis: IMC-βγ will decrease with disease progression.&#xD;
Because IMC-βγ measures functional input from motor neurons in the brain, it should decrease as these neurons are lost. IMC will be measured sequentially about every 3 months in patients with ALS, and will be compared to measures of clinical progression.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        AIM 1: The study population includes patients with symptomatology suggestive of ALS who are&#xD;
        referred to neuromuscular clinics at one of the four participating centers.&#xD;
&#xD;
        AIM 2: All healthy subjects between 20 and 80 years old.&#xD;
&#xD;
        AIM 3: Patients with suspected ALS who had an initially detectible IMC-βγ.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AIM 1: Patients with arm or leg weakness, spastic gait, muscle wasting and/or&#xD;
             fasciculations (muscle twitching), dysphagia (difficulty swallowing), dysarthria&#xD;
             (difficulty speaking), shortness of breath, hyperreflexia or pathological reflexes, or&#xD;
             findings of muscle denervation in previous needle electromyography (EMG) studies.&#xD;
&#xD;
          -  AIM 2: Subjects between 20 and 80 years of age.&#xD;
&#xD;
          -  AIM 3: Subjects will be selected from among Aim 1 patients who carry an Awaji (without&#xD;
             IMC) category of Possible, Probable, or Definite ALS.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AIM 1:&#xD;
&#xD;
               1. Classified as probable or definite ALS by Awaji criteria prior to initial study&#xD;
                  evaluation&#xD;
&#xD;
               2. Have significant sensory loss in the weak or spastic limbs&#xD;
&#xD;
               3. Have significant musculoskeletal or neuropathic pain&#xD;
&#xD;
               4. Have an inability or are unwilling to provide informed consent&#xD;
&#xD;
               5. Are unable to perform the study-related task&#xD;
&#xD;
               6. Are taking baclofen or benzodiazepines&#xD;
&#xD;
               7. Have a known non-ALS cause for symptoms&#xD;
&#xD;
          -  AIM 2:&#xD;
&#xD;
               1. Have a history of neurological disorders such as stroke, neuropathy, or myopathy&#xD;
&#xD;
               2. Have significant pain or sensory loss&#xD;
&#xD;
               3. Are taking baclofen or sedatives such as benzodiazepines&#xD;
&#xD;
               4. Lack of cognitive ability or willingness to provide informed consent&#xD;
&#xD;
          -  AIM 3:&#xD;
&#xD;
               1. Were unclassified according to the Awaji category or had a defined ALS mimic&#xD;
&#xD;
               2. Are taking baclofen, sedatives or benzodiazepines.&#xD;
&#xD;
        NOTE: Participation in a therapeutic clinical trial is NOT an exclusion criterion since&#xD;
        this study would not interfere with any potential interventions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kourosh Rezania, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Serdar Aydin, MD</last_name>
    <phone>(773)795-9908</phone>
    <email>serdarmd@neurology.bsd.uchicago.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shail Bhatnagar, MD</last_name>
    <phone>(773)702-1124</phone>
    <email>sbhatnagar@neurology.bsd.uchicago.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Center for Clinical Research</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Avelar</last_name>
      <phone>714-509-2665</phone>
      <email>jbavelar@hs.uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeanette Overton</last_name>
      <phone>(714)456-8520</phone>
      <email>jtoverto@hs.uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ali A Habib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Addy</last_name>
      <phone>617-726-4282</phone>
      <email>gaddy@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Geli Kane</last_name>
      <phone>(617) 726-1531</phone>
      <email>gckane@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William S David, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly McCoy-Gross</last_name>
      <phone>314-273-8215</phone>
      <email>kmccoygross@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sukrutha Thotala</last_name>
      <phone>(314) 273-7966</phone>
      <email>thotala.s@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Bucelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/27699797/</url>
    <description>Intermuscular coherence in amyotrophic lateral sclerosis: A preliminary assessment</description>
  </link>
  <results_reference>
    <citation>Issa NP, Frank S, Roos RP, Soliven B, Towle VL, Rezania K. Intermuscular coherence in amyotrophic lateral sclerosis: A preliminary assessment. Muscle Nerve. 2017 Jun;55(6):862-868. doi: 10.1002/mus.25426. Epub 2017 Feb 3.</citation>
    <PMID>27699797</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

